共 50 条
Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis
被引:22
|作者:
Mou, Shan
[1
]
Wang, Qin
[1
]
Li, Jialin
[1
]
Shi, Beili
[1
]
Ni, Zhaohui
[1
]
机构:
[1] Shanghai Jiao Tong Univ, Div Renal, Renji Hosp, Sch Med, Shanghai 200127, Peoples R China
关键词:
L-FABP;
Chronic glomerulonephritis;
Progression of renal disease;
RENAL-DISEASE;
ALBUMIN;
INJURY;
REGRESSION;
BIOMARKER;
OVERLOAD;
LESIONS;
DAMAGE;
RISK;
D O I:
10.1016/j.cca.2011.09.018
中图分类号:
R446 [实验室诊断];
R-33 [实验医学、医学实验];
学科分类号:
1001 ;
摘要:
Background: To evaluate the value of basal urinary L-FABP (uL-FABP) excretion as a prognostic indicator of the progression of kidney function impairment in patients with chronic glomerulonephritis (CGN). Methods: One hundred twenty-three patients with newly diagnosed, biopsy-proven primary CGN were included. In all patients, and in 28 healthy subjects, uL-FABP was measured using an ELISA. Risk factors of the progression of kidney function were evaluated. The patients were in follow-up for at least 5 years. Results: uL-FABP in the patients with CGN (76.58 +/- 17.3 mu g/g.cr) was greater than in the healthy subjects. A significant positive correlation between uL-FABP and proteinuria (R = 0.501, P<0.01), serum creatinine (R = 0.601, P<0.01) were found. Kaplan-Meier analysis revealed that uL-FABP >76.58 mu g/g.cr predicts progression of renal function. The cut off values for L-FABP at 119.8 mu g/g.cr was found to be more sensitive, area under the curve (AUC) was 0.95. Conclusion: Urinary L-FABP may be a useful clinical biomarker for monitoring chronic glomerular disease. Urinary L-FABP can help predict the progression of chronic glomerular disease. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:187 / 191
页数:5
相关论文